UNITED STATES
|
Delaware (State or Other Jurisdiction of Incorporation) |
0-28740 (Commission File Number) |
05-0489664 (IRS Employer Identification No.) |
100 Clearbrook Road,
Elmsford, New York (Address of Principal Executive Offices) |
10523 (Zip Code) |
Registrant's telephone number, including area code (914) 460-1600 |
|
(Former Name or Former Address, if Changed Since Last Report) |
Item 7. Financial Statements and
Exhibits. |
Exhibit
99.1 |
Description of Exhibit
Press Release issued by MIM Corporation on April 29, 2004 |
Item 12. Results of Operations and Financial Condition The press release dated
April 29, 2004 identified in Exhibit 99.1, and which announces earnings for our first quarter, includes "non-GAAP financial meaures" as defined by
SEC rules.
|
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized. |
Date: May 3, 2004 | MIM CORPORATION By: /s/ James S. Lusk James S. Lusk, Executive Vice President and Chief Financial Officer |
EXHIBIT INDEX |
Exhibit Number |
Description of Exhibit
Press Release issued by MIM Corporation on April 29, 2004 |
EXHIBIT 99.1 |
|
MIM Reports First Quarter EPS of $0.10
ELMSFORD, NY - April 29, 2004 - MIM Corporation (NASDAQ:MIMS) (CBOE:OQX) (PCX:OQX)
, a pharmaceutical healthcare organization, today reported first quarter 2004 results.
|
Richard H. Friedman, Chairman and Chief Executive Officer commented:
"2004 is off to a solid start. We have exceeded consensus estimates.
All of our businesses are performing well and overall Specialty therapies
are growing."
1 |
Operating income for the first quarter was $3.8 million compared to $5.9
million for the first quarter of 2003. Excluding the results from TennCare
and Synagis, operating income grew 64% from $2.3 million for the prior
year's quarter. (1)
2 |
MIM Corporation (www.mimcorporation.com) is a pharmaceutical healthcare
organization delivering innovative pharmacy benefit and healthcare solutions
that provide results beyond expectations. We excel by harnessing our
clinical expertise, sophisticated data management, and therapeutic fulfillment
capability, and combine it with our dedicated, responsive team of professionals
that understands our partners' needs. The result is cost-effective solutions
enhancing the quality of patient life.
Contacts: |
James S. Lusk Executive Vice President/Chief Financial Officer MIM Corporation 914-460-1648 Email: jlusk@mimcorporation.com |
Rachel Levine Investor Relations The Anne McBride Co. 212-983-1702 x.207 Email: rlevine@annemcbride.com |
(1) |
See Table of Reconciliation for the differences between the non-GAAP financial
measures and the most directly comparable GAAP measures. As required by Regulation G,
the Company has provided a quantitative comparison between the GAAP and disclosed
non-GAAP financial measures. The non-GAAP measures presented provide important
insight into the ongoing operations and a meaningful comparison of revenue, gross
profit, selling, general and administrative expenses, operating income, net
income and earnings per share.
FINANCIAL TABLES AND SUPPLEMENTAL DATA FOLLOW 3 |
4 |
5 |
6 |
7 |
8 |
9 |